Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Last trade$14.54
Day change+$0.01 (+0.07%)
Day range$14.33 – $14.80
Volume578,477
Market cap$1.29B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.29B
Price / earnings
—
Price / book
2.55×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.29×
Profitability
Earnings per share
-$4.18
Return on assets
-58.71%
Return on equity
-73.44%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.2×
Current ratio
11.83×
Quick ratio
11.83×
Cash ratio
1.91×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$153.03M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MLYS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$37.42M
$24.66M
$20.98M
$13.88M
$9.68M
$8.47M
$6.57M
$7.2M
Research and development
$22.67M
$221.38M
$24.37M
$24.4M
$31.45M
$38.28M
$37.88M
$44.57M
Total operating expenses
$60.09M
$246.04M
$45.34M
$38.28M
$41.13M
$46.75M
$44.45M
$51.77M
Operating income
-$60.09M
-$246.04M
-$45.34M
-$38.28M
-$41.13M
-$46.75M
-$44.45M
-$51.77M
Interest expense
-$3.19M
$4.96M
$6M
$0
$0
$3.47M
$2.24M
$0
Income before taxes
-$57.33M
-$241.07M
-$39.34M
-$32.23M
-$36.93M
-$43.27M
-$42.21M
-$48.95M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$57.33M
-$241.07M
-$39.34M
-$32.23M
-$36.93M
-$43.27M
-$42.21M
-$48.95M
Net income attributable to common shareholders
-$57.33M
-$241.07M
-$39.34M
-$32.23M
-$36.93M
-$43.27M
-$42.21M
-$48.95M
EBITDA
-$60.08M
-$246.04M
-$45.33M
-$38.27M
-$41.12M
-$46.73M
-$44.43M
-$51.75M
Basic earnings per share
-$0.64
-$2.85
-$0.47
-$0.40
-$0.52
-$0.66
-$0.79
-$0.98
Diluted earnings per share
-$0.64
-$2.85
-$0.47
-$0.40
-$0.52
-$0.66
-$0.79
-$0.98
Recent news
Company coverage with links to the original publishers.
Mineralys Therapeutics announced positive long-term results from the Transform-HTN open-label extension trial of lorundrostat, demonstrating sustained blood pressure reduction of 17.8 mmHg at Week 48, with 56% of participants achieving systolic blood pressure below 130 mmHg. The drug was well tolerated with no new safety concerns. The FDA review is underway with a PDUFA target date of December 22, 2026.
The obstructive sleep apnea (OSA) therapeutic landscape is rapidly expanding with 18+ companies developing 22+ pipeline drugs across multiple mechanisms of action. Eli Lilly's ZEPBOUND (tirzepatide) became the first FDA-approved pharmacological treatment for OSA in December 2024. Other major players including Apnimed, Amgen, Mosanna Therapeutics, and Incannex Healthcare are advancing late-stage candidates targeting weight loss, neuromuscular function, and airway control through diverse delivery methods.
Mineralys Therapeutics presented positive Phase 3 Launch-HTN trial data showing lorundrostat achieved significant blood pressure reductions in participants with and without chronic kidney disease, with a 52% reduction in albuminuria in CKD patients. The drug demonstrated an acceptable safety profile with low hyperkalemia rates and is under FDA review with a PDUFA target date of December 22, 2026.
Mineralys Therapeutics presented new clinical trial data for lorundrostat, its investigational aldosterone synthase inhibitor for treating difficult-to-treat hypertension. The Launch-HTN trial showed 46% of participants achieved AHA/ACC guideline systolic blood pressure targets (<130 mmHg) at 12 weeks, with over two-thirds achieving ≥10 mmHg reduction. The Explore-OSA trial demonstrated clinically meaningful morning blood pressure reductions in obstructive sleep apnea patients with no adverse effects on sleep apnea indices.
Mineralys Therapeutics announced that new data from the Launch-HTN Phase 3 clinical trial of lorundrostat, an investigational aldosterone synthase inhibitor, will be presented at the American Society of Nephrology Kidney Week 2026. The presentation will focus on blood pressure and albuminuria reduction in chronic kidney disease patients. Lorundrostat is being developed to treat uncontrolled and resistant hypertension, with the company having completed six late-stage clinical trials demonstrating efficacy and safety.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.